Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1975 Jun 14;112(13 Spec No):47–50.

Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole.

W T Hughes, S Feldman, S K Sanyal
PMCID: PMC1956451  PMID: 1079469

Abstract

Pneumocystis carinii pneumonitis (PCP) is fatal in 90 to 100% of the cases if no treatment is given. Trimethoprim-sulfamethoxazole (TMP-SMX) was used at one of two dosage levels in the treatment of 20 children with PCP and cancer. Of 14 patients treated with 20 mg TMP--100 mg SMX/kgd, 12 recovered and 2 died. Treatment of the fatal cases and one of the patients who recovered was supplemented with pentamidine. When six patients were treated with 4 to 7 mg TMP--20 to 35 mg SMX/kgd, four recovered and two died. Both fatal cases and one of the patients who recovered were also treated with pentamidine. There was no significant adverse effects from TMP-SMX.

Full text

PDF
47S

Images in this article

48SFIG. 1
on p.48S
49SFIG. 2
on p.49S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Frenkel J. K., Good J. T., Shultz J. A. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab Invest. 1966 Oct;15(10):1559–1577. [PubMed] [Google Scholar]
  2. Frisch J. M. Clinical experience with adverse reactions to trimethoprim-sulfamethoxazole. J Infect Dis. 1973 Nov;128(Suppl):607–p. doi: 10.1093/infdis/128.supplement_3.s607. [DOI] [PubMed] [Google Scholar]
  3. Hughes W. T., Johnson W. W. Recurrent pneumocystis carinii pneumonia following apparent recovery. J Pediatr. 1971 Nov;79(5):755–759. doi: 10.1016/s0022-3476(71)80387-6. [DOI] [PubMed] [Google Scholar]
  4. Hughes W. T., McNabb P. C., Makres T. D., Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1974 Mar;5(3):289–293. doi: 10.1128/aac.5.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hughes W. T., Price R. A., Kim H. K., Coburn T. P., Grigsby D., Feldman S. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr. 1973 Mar;82(3):404–415. doi: 10.1016/s0022-3476(73)80113-1. [DOI] [PubMed] [Google Scholar]
  6. Kirby H. B., Kenamore B., Guckian J. C. Pneumocystis carinii pneumonia treated with pyrimethamine and sulfadiazine. Ann Intern Med. 1971 Oct;75(4):505–509. doi: 10.7326/0003-4819-75-4-505. [DOI] [PubMed] [Google Scholar]
  7. Le Clair R. A. Descriptive epidemiology of interstitial pneumocystic pneumonia. An analysis of 107 cases from the United States, 1955-1967. Am Rev Respir Dis. 1969 Apr;99(4):542–547. doi: 10.1164/arrd.1969.99.4P1.542. [DOI] [PubMed] [Google Scholar]
  8. Rifkind D., Faris T. D., Hill R. B., Jr Pneumocystis carinii pneumonia. Studies on the diagnosis and treatment. Ann Intern Med. 1966 Nov;65(5):943–956. doi: 10.7326/0003-4819-65-5-943. [DOI] [PubMed] [Google Scholar]
  9. Ruskin J., Remington J. S. Pneumocystis carinii infection in the immunosuppressed host. Antimicrob Agents Chemother (Bethesda) 1967;7:70–76. [PubMed] [Google Scholar]
  10. Schwartz D. E., Koechlin B. A., Weinfeld R. E. Spectrofluorimetric method for the determination of trimethoprim in body fluids. Chemotherapy. 1969;14(Suppl):22–29. doi: 10.1159/000220652. [DOI] [PubMed] [Google Scholar]
  11. Western K. A., Perera D. R., Schultz M. G. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1970 Nov;73(5):695–702. doi: 10.7326/0003-4819-73-5-695. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES